×
About 365 results

ALLMedicine™ Waldenstrom Macroglobulinemia Center

Research & Reviews  111 results

Study of CLR 131 in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia
https://clinicaltrials.gov/ct2/show/NCT02952508

Dec 2nd, 2021 - B-cell malignancies represent a diverse collection of diseases and, taken together, make up the majority of hematologic malignancies. B-cell lymphomas represent the largest percentage of these neoplasms, and the relapsed and/or refractory B-cell l...

Post-relapse survival in Waldenstrom macroglobulinemia patients experiencing therapy fa...
https://doi.org/10.1002/hon.2946
Hematological Oncology; Ahmed S, Zhao Q et. al.

Nov 12th, 2021 - Waldenström macroglobulinemia (WM) is a rare B-cell lymphoproliferative malignancy. Autologous hematopoietic cell transplantation (auto-HCT) is considered in a subset of WM patients with relapsed disease. While registry data has shown a benefit fo...

Bing-Neel Syndrome: Update on the Diagnosis and Treatment.
https://doi.org/10.1016/j.clml.2021.09.014
Clinical Lymphoma, Myeloma & Leukemia; Nanah A, Al Hadidi S

Oct 23rd, 2021 - Bing-Neel syndrome (BNS) is a rare syndrome that occurs in patients with Waldenstrom macroglobulinemia and is characterized by lymphoplasmacytic infiltration into the leptomeningeal tissue and/or the central nervous system. It represents an extram...

Bortezomib enhances the anti-cancer effect of the novel Bruton's tyrosine kinase inhibi...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457562
Aging Wang X, Fei Y et. al.

Sep 12th, 2021 - BGB-3111, a novel Bruton's tyrosine kinase (BTK) inhibitor, shows promising anti-cancer effects in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), mantle cell lymphoma (MCL), and Waldenstrom macroglobulinemia (WM). This study ai...

see more →

Clinicaltrials.gov  4 results

Study of CLR 131 in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia
https://clinicaltrials.gov/ct2/show/NCT02952508

Dec 2nd, 2021 - B-cell malignancies represent a diverse collection of diseases and, taken together, make up the majority of hematologic malignancies. B-cell lymphomas represent the largest percentage of these neoplasms, and the relapsed and/or refractory B-cell l...

Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation
https://clinicaltrials.gov/ct2/show/NCT05023655

Aug 26th, 2021 - AT rich interacting domain containing protein 1A (ARID1A) is a tumor suppressor gene frequently mutated in solid tumor malignancies, often loss of function mutations (frameshift or non-sense). ARID1A encodes a large nuclear protein BAF250a, a vita...

Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders
https://clinicaltrials.gov/ct2/show/NCT01177527

Feb 2nd, 2021 - Participants will be asked to complete a medical survey which includes demographics, diagnosis, and treatment history, medical history, lab results and symptoms experienced. Participants will then receive instructions for the tissue banking proced...

S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macrog...
https://clinicaltrials.gov/ct2/show/NCT00723658

Mar 6th, 2015 - OBJECTIVES: Primary To assess the progression-free and overall survival of patients with symptomatic Waldenstrom macroglobulinemia treated with bortezomib, dexamethasone, thalidomide, cisplatin, doxorubicin hydrochloride, cyclophosphamide, and eto...

see more →

News  24 results

When to Treat as Important as Which Drug to Use in WM
https://www.medscape.com/viewarticle/961877

Oct 29th, 2021 - When to initiate treatment is as important as what to use for the treatment of patients newly diagnosed with Waldenstrom macroglobulinemia (WM), a leading expert in the disease emphasizes. "We have to be very careful not to tell patients they have...

Waldenstrom Macroglobulinemia: Non-BTK Novel Strategies
https://www.onclive.com/view/waldenstrom-macroglobulinemia-non-btk-novel-strategies

Apr 2nd, 2021 - Transcript: Ian W. Flinn, MD, PhD: Let’s get away from BTK inhibitors in Waldenström macroglobulinemia. They’re clearly a really important addition to our armamentarium for this disease. What else excites you? John, is there anything else that...

Ibrutinib's Role as Frontline Therapy in CLL
https://www.onclive.com/view/ibrutinibs-role-as-frontline-therapy-in-cll

Apr 2nd, 2021 - Transcript: Ian W. Flinn, MD, PhD: Hello, and thank you for joining us for this OncLive Peer Exchange® titled, Updates in Targeted Therapies for B-Cell Malignancies. I’m joined by a group of my colleagues who are renowned experts in B-cell mal...

FDA Approvals in Follicular Lymphoma and Prostate Cancer, Biosimilar Is Granted Approval, and More
https://www.onclive.com/view/fda-approvals-in-follicular-lymphoma-and-prostate-cancer-biosimilar-is-granted-approval-and-more

Apr 2nd, 2021 - Today- FDA approvals in follicular lymphoma and prostate cancer, a biosimilar approved for several cancers, a new drug application in prostate cancer, results from 2 late-stage prostate cancer trials, and encouraging findings in a chronic lymph...

FDA Approval in Melanoma, Priority Reviews in AML and WM, NDAs in Melanoma and SCLC, and More
https://www.onclive.com/view/fda-approval-in-melanoma-priority-reviews-in-aml-and-wm-ndas-in-melanoma-and-sclc-and-more

Apr 2nd, 2021 - Today- An FDA approval in melanoma, priority review designations in acute myeloid leukemia and Waldenstrom macroglobulinemia, new drug applications accepted in melanoma and non-small cell lung cancer, and additions to immunotherapy labels in bl...

see more →

Patient Education  7 results see all →